Obtaining clinical samples for genetic research
All CPCT locations are currently hosting the so-called CPCT-02 study in which patients with advanced or metastasized cancer who will be receiving a standard treatment with anti-cancer medication are being asked to undergo a tumor biopsy prior to treatment start. The major aim of this study is to establish whether the DNA profile of a tumor can be used to predict to outcome to the therapy received. Patients can only participate if we believe that performing a tumor biopsy is safe. In the next stage isolated DNA is sequenced as we look at all known predictive/prognostic biomarkers and search for new biomarkers for response and/or survival. This takes place based on the radiological imaging such as CT-scanning during the treatment with anti-cancer medication.
Additionally, for some patients, in particular for those for whom no standard treatments are available anymore, the genetic information of the tumor may already be used to identify clinical studies for which patients may be suitable candidates.
In the future we expect to be able to offer patients a treatment proposal based on the genetic makeup of the metastasis. The CPCT has the required logistics already in place between clinic, sequencing facility (the partnership with Hartwig Medical Foundation), bioinformatics analysis and data interpretation. We discuss the data in a multidisciplinary team after which we draw up a recommendation for the attending physician.
We provide each patient with detailed information about the procedure for determining the genetic makeup of the metastasis in order to decide the therapy. We also tell patients about the complication risks of the biopsy procedure.
The Radiology department and the Gastric, Intestinal and Liver department where patients undergo the biopsy are closely involved. The Pathology department also plays an important role in processing and processing the biopsies. Histologic evaluation takes place with the quality control of the biopsy in which the representativeness of the biopsies and the tumor percentage are studied. There are various quality standards for the sequencing process. After sequencing, the data is analyzed and interpreted with bioinformatics and statistics tools. The results are then communicated to the attending physician who discusses the treatment strategy with the patient.
The various clinical studies take place at all CPCT locations. The sequencing facilities are located at the premises of the Hartwig Medical Foundation (Amsterdam Science Park).